# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
23andMe's independent board members resigned after months of waiting for Anne Wojcicki's fully financed proposal to tak...
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer.Elevated levels of s...
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one con...
23andMe Holding (NASDAQ:ME) reported quarterly losses of $(0.14) per share. The company reported quarterly sales of $40.000 mi...